34 citations,
December 2012 in “Current Opinion in Clinical Nutrition and Metabolic Care” Sex hormone treatments can increase muscle mass in older adults but have inconsistent effects on muscle function and may carry cardiovascular risks.
14 citations,
September 2017 in “Clinics in Dermatology” Skin diseases linked to insulin resistance should be managed to prevent diabetes and reduce heart disease risk.
42 citations,
July 2015 in “Journal of The American Academy of Dermatology” The conclusion is that oral contraceptives and antiandrogens can treat hirsutism and acne in women with cutaneous hyperandrogenism, but more research is needed for effective treatments, especially for hair loss.
21 citations,
November 2014 in “Journal of Endocrinological Investigation” Cross-sex hormone therapy is important for managing gender dysphoria and requires careful monitoring and healthcare provider education.
18 citations,
February 2010 in “Odontology” The document concludes that Rabson-Mendenhall syndrome requires novel treatments for insulin resistance and emphasizes the importance of dental care in affected patients.
August 2024 in “Drug Design Development and Therapy” Decursin shows promise for treating cancer, neuroprotection, inflammation, and hair loss.
223 citations,
December 2010 in “The Journal of Sexual Medicine” Some patients taking finasteride or dutasteride may have ongoing sexual problems and depression even after stopping the medication.
13 citations,
May 2018 in “Urologic Oncology: Seminars and Original Investigations” Finasteride does not prevent bladder cancer.
September 2009 in “European Urology Supplements” IGRT resulted in lower acute toxicity for stage III prostate cancer patients.
February 2018 in “The Journal of Sexual Medicine” Natesto nasal gel improves erectile function and mood in men with low testosterone within 30 days.
May 2011 in “Expert Review of Endocrinology & Metabolism” Breast cancer survivors may have a higher risk of falls, tamoxifen could prevent breast cancer and deaths, new guidelines urge caution with prostate cancer therapy, and early balding in men may indicate a higher prostate cancer risk.
10 citations,
February 2008 in “International Journal of Andrology” A combination of nanomilled oral testosterone and dutasteride normalized testosterone levels in men with low testosterone and is safe for short-term use.
November 2020 in “Journal of The American Academy of Dermatology” Men with male pattern baldness may be more at risk for severe COVID-19, and anti-androgen treatments could offer protection.
June 2023 in “Journal of Cosmetic Dermatology” The treatment combining platelet-rich plasma and a non-cross-linked hyaluronic acid compound significantly improved hair density and reduced bald areas in women with androgenetic alopecia, and it's safe with only mild side effects.
14 citations,
January 2018 in “Advances in Clinical Chemistry” The document concludes that hormonal biomarkers are key for diagnosing hyperandrogenemia in women and hypogonadism in men.
May 2022 in “Current Enzyme Inhibition” Compound 7b is a promising candidate for treating benign prostatic hyperplasia and prostate cancer.
January 2019 in “Oncogen” Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.
18 citations,
November 2012 in “Current opinion in urology” Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.
10 citations,
June 2018 in “Aaps Pharmscitech” The flutamide-loaded hydrogel is a promising, skin-friendly treatment for acne and hair loss, potentially requiring less frequent application.
January 2015 in “American journal of medical and biological research”
108 citations,
February 2008 in “The Journal of urology/The journal of urology” Inhibiting 5α-reductase can help reduce prostate cancer risk and improve treatment.
11 citations,
January 2014 in “Egyptian Journal of Dermatology and Venereology” Women losing hair might have lower levels of vitamin D.
15 citations,
December 2006 in “Clinical interventions in aging” 5 alpha-reductase inhibitors like finasteride may lower prostate cancer risk and improve cancer screening.
32 citations,
May 2006 in “The Journal of Urology” Using finasteride with TIP extends time off period for prostate cancer patients.
11 citations,
January 1991 in “Urology” New hormonal treatments for enlarged prostate show promise for safer, effective non-surgical options.
17 citations,
December 2015 in “BMC Complementary and Alternative Medicine” A new plant extract from Avicennia marina could potentially be used to treat common hair loss.
November 2022 in “The Journal of Urology” Adopting the Mark Cuban Cost Plus Drug Company pricing model could save Medicare about $1.29 billion on urological drugs.
April 2024 in “Prostate international” Male pattern baldness does not cause an increased risk of prostate cancer.
5 citations,
April 2021 in “Journal of Endocrinological Investigation” Higher DHT levels are linked to fewer hypogonadism symptoms in men with normal testosterone levels.
35 citations,
January 2002 in “Scandinavian Journal of Urology and Nephrology” Finasteride reduces prostate bleeding by affecting blood vessel growth.